首页> 外文OA文献 >Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial

【2h】

Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial

机译：随后的免疫检查点抑制剂治疗对铂治疗高级NSCLC中Avelumab Vs Docetaxel的整体存活的影响：从第3阶段3枪肺200次试验中分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Keunchil Park; Mustafa Özgüroğlu; Johan Vansteenkiste; David Spigel; James C.-H. Yang; Marcis Bajars; Mary Ruisi; Juliane Manitz; Fabrice Barlesi;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study [J] . Barlesi Fabrice, Vansteenkiste Johan, Spigel David, The lancet oncology . 2018,第11期

机译：Avelumab对多西紫杉醇的铂治疗的晚期非小细胞肺癌（Javelin Lung 200）：开放标签，随机，第3期研究
2. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study (vol 19, pg 1468, 2018) [J] . Barlesi F., Vansteenkiste J., Spigel D. The lancet oncology . 2018,第11期

机译：Avelumab与多西紫杉醇患者铂治疗的先进非小细胞肺癌（Javelin Lung 200）：开放标签，随机，第3阶段研究（Vol 19，PG 1468,2018）
3. OA05.05 Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial [J] . F. Barlesi, J. Vansteenkiste, D. Spigel, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：AA05.05 Avelumab VS Docetaxel用于先前处理的高级NSCLC：第3阶段阶段的主要分析200试验
4. Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials [O] . Karen Kelly, Jeffrey R. Infante, Matthew H. Taylor, -1

机译：avelumab在晚期实体瘤患者中的安全性概况：JAVELIN 1期实体瘤和2 JAVELIN Merkel 200期临床试验数据的汇总分析
5. Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC) [O] . F. Barlesi, M. Özgüroğlu, J.F. Vansteenkiste, 2019

机译：评估随后的检查点抑制剂（CPI）治疗总体存活的影响：从铂治疗的局部晚期/转移性非小细胞肺癌（NSCLC）中Avelumab vs多西紫杉醇的III型Javelin肺200研究。
6. Phase 1 Trial of an Immune Checkpoint Inhibitor plus Stereotactic Ablative Radiotherapy in Patients with Inoperable Stage I Non-Small Cell Lung Cancer. [R] . Kelly, K., Monjazeb, A., Daly, M., 2017

机译：免疫检查点抑制剂加立体定向消融放疗治疗不能手术的I期非小细胞肺癌的1期试验。

Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial

著录项

引文网络

相似文献

相关主题

期刊订阅